Dr. Shridhar Narayanan, Director, FNDR has more than 12 years of drug discovery and development experience in the Indian pharmaceutical industry in various therapeutic areas. Shridhar holds a basic degree in Pharmaceutical Sciences, a PhD in Pharmacology from Ohio State University, and has post-doctoral experience in Neuro-pharmacology at the University of California, Los Angeles. Shridhar has been the Executive Vice President-Discovery Biology and Drug Development at Orchid Chemicals and Pharmaceuticals. In this role, Shridhar has been responsible for the design and implementation of the scientific and business strategy for drug discovery and development across therapeutic areas, managing a team of scientists in biology, DMPK, safety pharmacology, and regulatory toxicology and clinical development. Most recently, Shridhar was appointed Vice President and Head of Innovative Science for the Infection at AstraZeneca, India and led the discovery and development of 2 potential clinical candidates in TB and malaria.
Throughout his career, Shridhar has contributed to the Discovery and Development of 15 clinical candidates. He has also executed out-licensing deals with major pharma as well as in-licensing of candidates (NCE/NBE) which are in active development. This has generated revenues in excess of 100 million USD. Shridhar has been a member of joint research committees, academic and industry collaborations and has served as a Ph.D. guide. Shridhar is a scientific consultant and advisor to biotech companies and Research Institutions and holds Adjunct faculty position at Transdisciplinary University, Bangalore.
Dr. R.K. Shandil is PhD in Immunology from the Post Graduate Institute of Medical Education Research (PGIMER), Chandigarh, India and brings a strong track record of scientific expertise in experimental parasitology, parasite immunology and hybridoma technology.
Dr.Shandil, Director, FNDR, served AstraZeneca India R&D, Bangalore, for 20 years in various scientific and managerial roles at Infection – innovative medicines group. Shandil was Head of DMPK & Animal Sciences and led multidisciplinary teams in biology, immunology and pharmacology. He played a central role in building microbiology, cell biology and Pharmacology based drug discovery platforms for infectious diseases.
He was instrumental in building and managing state of the art bio-safety laboratories, a Vivarium, and validating animal models of tuberculosis, malaria and serious bacterial infections, PKPD and Pharmacology at AstraZeneca R&D Bangalore. Shandil’s scientific leadership led to discovery and pre-clinical development of AZD 5847, an oxazolidinone class of compound that has now completed Phase 2a/EBA clinical trial in TB patients. He led pharmacology of several TB and malaria lead optimization (LO) programs. His most recent & significant contribution includes discovery of Azaindoles, a yet-another clinical candidate for TB [Shirude. P et.al. Antimicrobial Agents and Chemotherapy, 2014, 58:5325-31]. He holds/shares patents for discovery of AZD 5847 and Azaindole class of compounds for the treatment of tuberculosis. He has ~35 publications in peer reviewed national and international journals, a dozen of them in very prestigious drug discovery journals like Antimicrobial Agents and Chemotherapy, Journal of Medicinal Chemistry, Tuberculosis and Science. Shandil is scientific consultant and advisor to biotech companies and Research Institutions and holds Adjunct faculty position at Transdisciplinary University, Bangalore.
P. Gopal Krishnan, Director, FNDR, is responsible for Finance, Legal Compliance and Infrastructural Operations of FNDR.
Gopal is a member of the Institute of Chartered Accountants of India. He has worked in various functions including Finance, Information Management and Supply Chain for over a decade and a half. He headed the Shapoorji Pallonji Biotech Park, Hyderabad, was responsible for finance, supply chain and information management at Ortho-Clinical Diagnostics, Johnson & Johnson Ltd, and started up KARD Scientific India Private Limited, Pune, a drug discovery laboratory. He is currently the Principal Consultant & Director of Stabaka Consulting Private Limited, a business consulting company. He brings to the FNDR team, extensive leadership experience with significant cross-industry, cross-functional and cross-border exposure.
Dr. Vijay Potluri has over 12 years of experience in the pharmaceutical industry in both drug discovery and contract research. Vijay has a Master’s degree in Chemistry from Sri Satya Sai University, a Ph.D. in Supramolecular Chemistry from Indian Institute of Science, Bangalore and has done post-doctoral research at Yale University. In a career spanning over a decade in Discovery Chemistry at Dr. Reddy’s Laboratories, Vijay has led several Drug Discovery programs, delivering multiple clinical candidates. He has worked on diverse therapeutic areas ( metabolic disorders, cancer, inflammation, anti-infective, pain, etc. ) and on a wide a range of target classes ( kinases, GPCRs, ion channels, nuclear hormone receptors ). In his last assignment as Associate Director at Aurigene Discovery Technologies, Vijay managed collaborative programs with US and European pharma companies and was responsible for achieving multimillion dollars as milestones for several Discovery and Contract Research Programs.
Vijay is currently associated with the Foundation for Neglected Disease Research as Principal Scientist-Medicinal Chemistry and is responsible for the chemistry strategy within FNDR.
Dr. Parvinder Kaur is an established scientist with more than 25 years of experience in Research and Development in the area of infectious diseases. She holds Ph.D. in Microbiology and Molecular Biology from Vellore Institute of Technology (VIT) University, Vellore; and M. Phil., M.Sc. degrees in Medical Microbiology, from Himachal Pradesh University.
Her multi-disciplinary expertise ranges from Vaccines, infection Drug Discovery, Antisense RNA (AS-RNA) Technology, Microbial and Molecular- screening and validation platforms, high throughput screening for lead identification; and building efficiency through DMTA cycles and Lean-Six-Sigma. She has made significant contributions to antibacterial drug discovery through screening of MDR/XDR strains of TB and drug resistant superbugs. Parvinder started her scientific career from R&D in Vaccines & Biologicals and moved to Drug-Discovery, Research Management and regulatory compliance; while working at different institutes (Central Research Institute Kasauli, AstraZeneca Bangalore, and Bangalore Bio-innovation Centre, Bangalore). In her previous job at AstraZeneca, she has immensely contributed to the development of AZD5847 (an oxazolidinone), and TBA7371 (a dprE inhibitor), currently in late stage pre-clinical development. She developed and validated AS-RNA Technology to delineate bactericidal targets for TB drug discovery. She has >30 high impact research publications to her credit.
Parvinder also has a strong background in Biosafety, General Laboratory standards, Health Safety & Environment (HSE), Human biological samples (HBS), and compliance requirements to regulatory bodies (IBSC, RCGM, DBT, DCGI etc.). In the capacity of Bio-safety officer, she has been accountable for the organisational Bio-safety, Bio-Banks, third party audits, Bio-safety trainings and certifications of the employee-scientists. As an ISO 9001:2015 QMS & ISO 14001:2015 certified Internal-Auditor, she has been consultant in Bio-safety, HSE, and Microbiology for few pharma companies.
A scientific advisory board of leaders in the field of TB and malaria research will be constituted by Q2-2017 to ensure that the overall deliverables of FNDR are in line with the global objectives for combating these diseases.